Grace Therapeutics Files 8-K

Ticker: GRCE · Form: 8-K · Filed: Apr 9, 2025 · CIK: 1444192

Grace Therapeutics, INC. 8-K Filing Summary
FieldDetail
CompanyGrace Therapeutics, INC. (GRCE)
Form Type8-K
Filed DateApr 9, 2025
Risk Levellow
Sentimentneutral

Sentiment: neutral

Topics: corporate-filing, reporting

TL;DR

Grace Therapeutics (formerly Acasti Pharma) filed an 8-K on 4/9/25. Standard reporting.

AI Summary

Grace Therapeutics, Inc. filed an 8-K on April 9, 2025, reporting other events and financial statements. The company, formerly known as Acasti Pharma Inc. until August 28, 2008, is incorporated in Delaware and headquartered in Princeton, New Jersey.

Why It Matters

This filing indicates ongoing corporate reporting and potential updates regarding Grace Therapeutics' financial status or significant events.

Risk Assessment

Risk Level: low — This is a routine filing for corporate reporting and does not appear to contain any immediately alarming information.

Key Numbers

Key Players & Entities

FAQ

What specific 'Other Events' are being reported in this 8-K?

The filing indicates 'Other Events' as an item information, but the specific details of these events are not provided in the provided text.

What is the SIC code for Grace Therapeutics, Inc.?

The Standard Industrial Classification (SIC) code for Grace Therapeutics, Inc. is 2834, which corresponds to Pharmaceutical Preparations.

When did the company change its name from Acasti Pharma Inc.?

The company's name was changed from Acasti Pharma Inc. on August 28, 2008.

What is the fiscal year end for Grace Therapeutics, Inc.?

The fiscal year end for Grace Therapeutics, Inc. is March 31.

What is the business address of Grace Therapeutics, Inc.?

The business address of Grace Therapeutics, Inc. is 103 Carnegie Center, Suite 300, Princeton, New Jersey 08540.

Filing Details

This Form 8-K (Form 8-K) was filed with the SEC on April 9, 2025 regarding Grace Therapeutics, Inc. (GRCE).

View full filing on EDGAR

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing